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Background: Resequencing of deafness related genes using GS FLX massive parallel sequencing of PCR amplicons
spanning selected genes has previously been reported as a successful strategy to discover causal variants. The
amplicon lengths were designed to be smaller than the sequencing read length of GS FLX technology, but are
longer than Illumina sequencing technology read lengths. Fragmentation is thus required to sequence these
amplicons using high throughput Illumina technology.
Methods: We performed Illumina sequencing in 4 patients on 563 multiplexed amplicons covering the exons of
15 genes involved in the hearing process. After exploring several fragmentation strategies, the amplicons were
fragmented using Covaris sonication prior to library preparation. CLC genomic workbench was used to analyze the data.
Results: We achieve an excellent coverage with more than 99% of the amplicons bases covered. All variants that were
previously validated using Sanger sequencing, were also called in this study. Variant calling revealed less false positive
and false negative results compared to the previous study. For each patient, several variants were found that are
reported by ClinVar as possible hearing loss variants.
Conclusion: Migration from GS FLX amplicon sequencing to Illumina amplicon sequencing is straightforward and leads
to more accurate results.Background
Hearing loss (HL) is quite common with one in 500
newborns having bilateral permanent sensorineural HL
of more than 40 dB HL [1]. In more than 50% of the
cases, hearing loss (HL) originates from mutations in
one of the many genes related to the hearing process. In
most cases, inherited HL is monogenic, but unfortu-
nately it is an extremely heterogeneous trait, with over
60 implicated genes (Hereditary Hearing Loss Home-
page; http://hereditaryhearingloss.org) making it a real
challenge for molecular diagnostics.
Recently, we published a study using semi-automated
PCR amplification and Roche GS FLX sequencing in
order to screen 15 autosomal recessive deafness genes in
5 patients with congenital genetic deafness [2]. A total of
646 specific primer sets for all exons and most of the* Correspondence: Filip.VanNieuwerburgh@UGent.be
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article, unless otherwise stated.UTR’s of the 15 selected genes were designed. In this
study, we analyzed the exact same PCR products using
Illumina GAIIx sequencing. The main reason to investi-
gate this, is the higher throughput of Illumina technol-
ogy. This experiment compares Roche GS FLX and
Illumina sequencing without changing any other vari-
ables. It also shows the possibility of performing Illu-
mina sequencing on amplicons that were prepared for
Roche GS FLX sequencing and shows the possibility of
sequencing amplicons that are longer than the Illumina
paired-end read length. Peer reviewed reports on sequ-
encing of fragmented amplicons is scarce: A review by
Mamanova et al. discusses target-enrichment strategies for
next-generation sequencing. A method for generation se-
quencing of fragmented long range PCR amplicons is re-
ported and the caveats are discussed [3]. Harismendy and
Frazer report a method for improving sequence coverage
uniformity of targeted genomic intervals amplified by long
range PCR using Illumina sequencing-by-synthesis tech-
nology [4].ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Patient material, primer design and amplicon PCR
For this study, no additional primer design or PCR was
performed. PCR products were obtained from the previ-
ous study for 4 of the 5 HL patients. Patients 1–4 corres-
pond to patients 1–3 and 5 in the previous study. Ethical
approval was obtained for all patients during the previous
study at the university of Antwerp ethical committee. The
fifteen autosomal recessive deafness genes (TMPRSS13,
TMI, TECTA, SLC26A4, PCDH15, OTOF, GJB2, ESRRB,
ESPN, CDH23, MYO7A, PJVK (DFNB59), MYO15A,
TMC1, TRIOBP) were selected, based on their reported
high mutation frequency [5]. The 646 PCR products cover
all the coding sequences (CDS) and most of the UTR’s of
the 15 genes. All PCR reactions were performed as single-
plex PCRs with the same PCR reaction conditions (See [2]
for details). The used primer sequences are detailed in
Additional file 1: Table S1. The average generated ampli-
con length over the 646 PCR’s is 319 bp, resulting in an
aggregate target size of approximately 0.2 Mb. The used
primers are modified at their 5′ end with a universal M13
linker sequence for GS FLX sequencing. For each patient,
563 PCR products were equimolarly pooled to obtain an
equal representation of every amplicon in the pool. The
rest of the 646 PCR products were left out of the pool be-
cause the PCR product was exhausted in the previous
study (detailed in Additional file 1: Table S1).
Illumina sequencing
For Illumina GAIIx paired-end sequencing (2x100 bp) of
amplicons bigger than 200 bp, these amplicons need to
be fragmented. It is crucial that this fragmentation oc-
curs as random as possible, to obtain an even read depth
across the amplicons. Several fragmentation strategies
were explored. One strategy was to concatenate the PCR
products before fragmentation with Fast-Link DNA
Ligation Kit (Epicentre Biotechnologies). The idea was
to create longer DNA strands which might be easier to
fragment randomly. This procedure requires substan-
tially more DNA, takes longer, requires more hands on
work, is more expensive and in the end provided no ad-
vantage over direct fragmentation of the amplicons in
terms of coverage. For this reason, the data of these ana-
lyses are not shown in this report. For the fragmentation
itself, we compared fragmentation with NEBNextTM
dsDNA Fragmentase (NEB) with fragmentation using
the Covaris S2. The distribution of the fragment lengths
was much smaller with the Covaris protocol. Further-
more, the enzymatic fragmentation is not robust and
DNA-concentration, enzyme concentration, incubation
time and temperature should be tightly controlled. Even
then, the yield of the desired fragments is low. Finally,
the samples were fragmented using the Covaris S2 with
following settings: Duty Cycle: 5% - Intensity: 5 - Cyclesper burst: 200 - Time: 12 minutes. The fragments were
used in a standard Illumina genomic sample preparation,
cluster generation and 2x100 bp paired-end sequencing
on an Illumina GAIIx sequencer.
Data analysis
Using Cutadapt (http://code.google.com/p/cutadapt/), the
sequences were trimmed for the M13 linker sequences.
Using an in house developed perl script, the reads were
trimmed when the average quality in a sliding window of
10 bp falls below 25 and filtered for sequences shorter
than 30 bp after trimming. The remaining sequences were
analyzed using CLC genomics workbench version 6.5. The
reads were paired end mapped to the haploid human ref-
erence sequence hg 19 (GRCh37) using a mask for the tar-
get regions of the used amplicons. Single nucleotide
variants and short insertions and deletion were called
using the CLC quality-based variant detection tool. Reads
that did not map uniquely and broken pairs were ignored.
Only variants with a coverage of at least 10 and a mini-
mum variant frequency of 35% were called. The require-
ment that variants should be present more or less equally
in forward and reverse reads was not used because this
lead to too many false negatives. We explored the advan-
tage of paired end (PE) mapping versus single end (SE)
mapping: On average SE mapping results in 25% more
called variants. Manual evaluation by comparing the PE
and SE mappings on a subset of these extra variants re-
vealed that most of these variants are likely to be false
positives due to incorrect mapping of e.g. short SE
reads. SE mapping is less stringent compared to PE
mapping. In an amplicon sequencing setting, incorrect
mappings can be propagated due to the many duplicate
reads originating from identical amplicons, leading to a
substantial increase of the number of incorrectly called
variants. The paired-end variants were annotated using
CLC and the ClinVar [6] database (ftp.ncbi.nih.gov/snp/
organisms/human_9606/VCF/clinvar_00-latest.vcf.gz 05
Nov 2013 10:27:36) to find variants that might be in-
volved in hearing loss. The amino acid changes caused
by the variants were also calculated using CLC.
Results
Coverage
The number of generated raw paired-end 2x100bp reads
for patient 1 to 4 was 12.8 × 106, 8.6 × 106, 3.2 ×106 and
3.0 × 106 respectively. Trimming for the M13 sequence,
trims approximately 5% of the bases. After the subse-
quent quality trimming and filtering, 11.9 × 106, 7.9 ×
106, 2.9 × 106 and 2.8 x106 reads remained with an aver-
age length of 85 bp. These reads have been deposited in
the EMBL-EBI European Nucleotide Archive (ENA) with
study accession PRJEB6747 and is available at http://www.
ebi.ac.uk/ena/data/view/PRJEB6747. The percentage of
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shown in Table 1.
Called variants
On average 172 variants were called in the 4 patients.
The called variants can be found in Additional file 2:
Table S2. The number of snps and indels called by CLC
on the Illumina data and the numbers of snps and indels
previously called by the VIP pipeline on the GS FLX data
can be compared in Additional file 3: Table S3. All 5 var-
iants that were previously found by the VIP pipeline and
validated using Sanger sequencing, were also called by
CLC in the Illumina data. The variants that were anno-
tated by ClinVar as deafness related or as highly pene-
trant, can be found in Additional file 4: Table S4.
Discussion
We performed Illumina sequencing on multiplexed
amplicons that were designed for GS FLX sequencing.
Using the exact same PCR products, we achieve an ex-
cellent coverage with more than 99% of the amplicons
bases covered and around 98% of the bases covered with
a depth greater than 5. This setup is not ideal to evaluate
the performance of Illumina sequencing because the
amplicons were generated using Roche specific fusion
primers and the amplicons therefore contain uninforma-
tive sequences that will be sequenced by the Illumina
technology. Furthermore, the amplicons are larger than
the 200 bp, making it necessary to fragment the ampli-
cons before they are sequenced. It is expected that the
performance of Illumina sequencing should only in-
crease when the amplicons would be generated with
analogous primers that do not contain the Roche GS
FLX adapter sequences. Nevertheless, we demonstrate
that excellent results can be obtained in this setting with
a simple Covaris sonication and a standard Illumina sam-
ple prep. A higher sequencing depth can be obtained at a
lower cost compared to GS FLX sequencing. Furthermore,
Sanger sequencing of homopolymer containing regions isTable 1 Coverage results are shown for paired end mapping
Patient 1
Number of raw Illumina GAIIx reads 12.81E + 06
Number of trimmed, quality filtered reads 11.92E + 06
Mapped reads - Single end 98.77%
Mapped reads - Paired end 99.02%
(properly paired) (97.71%)
Completely covered amplicons 557/563
Average depth 13064
% of amplicon bases with depth > 0 99.42%
% of amplicons bases with depth > 5 98.68%
Results for single end mapping are practically equal.not necessary because Illumina sequencing can correctly
sequence these regions. Only about half the number of
variants is called by CLC on the Illumina dataset com-
pared to the VIP pipeline on the 454 dataset. All 5 deaf-
ness associated variants that were previously confirmed by
Sanger sequencing were present in the CLC variant calls,
while the unconfirmed variant was not present. This hints
at the fact that the CLC variants contain less false positives
and false negatives compared to the VIP variants. Several
of the variants called by CLC are annotated as hearing loss
related or as being highly penetrant and deleterious. The
hearing loss related variants from all patients were
checked using dbSNP [7] and a literature study. For pa-
tient 3, we also checked all variants that were marked as
highly penetrant, because no definitive causal variants
were found for this patient in the previous study. All vari-
ants had a minor allele frequency that is too high to be a
causal variant or were reported in deafness related publi-
cations as neutral changes [8-11].Conclusion
Sequencing with Illumina technology of amplicons that
were designed for Roche GS FLX sequencing results in
excellent coverage after simple fragmentation of the
amplicons using a Covaris sonication. All exons of 15
deafness related genes were more than 99% covered,
leading to less false positive and false negative called var-
iants. For each patient, several variants were found that
are reported by ClinVar as possible hearing loss variants.
Migration from GS FLX amplicon sequencing to Illu-
mina amplicon sequencing is straightforward and leads
to more accurate results.Consent
Written informed consent was obtained from the pa-
tients for publication of these findings in scientific jour-
nals. A copy of the written consent is available for
review by the Editor of this journal.Patient 2 Patient 3 Patient 4
8.56E + 06 3.15E + 06 3.03E + 06
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Additional file 1: Table S1. Primer sequences covering 15 deafness
genes.
Additional file 2: Table S2. Called variants on 15 deafness genes.
Additional file 3: Table S3. Comparison number of variants between
GS FLX and Illumina data.
Additional file 4: Table S4. “Variants annotated by ClinVar as deafness
related”.
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